Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356576 · ClinicalTrials.gov registry record
Effect of Hemodialysis Membranes on Platelet Count
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 99
- Enrollment target
NCT01356576: Completed study, sponsored by Northwell Health.
NCT01356576 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01356576 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the Fresenius Optiflux® to check if it causes a drop in platelets.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-09 |
What the finished NCT01356576 record still lists
NCT01356576 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01356576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01356576 about?
NCT01356576 is a clinical study titled "Effect of Hemodialysis Membranes on Platelet Count". The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the Freseniu...
What is the current status of trial NCT01356576?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2010-09. Estimated completion is 2011-09.
Who is sponsoring clinical trial NCT01356576?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia